GNLX - GENELUX Corp

2.8
-0.030   -1.071%

Share volume: 111,330
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$2.83
-0.03
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 43%
Dept financing 24%
Liquidity 58%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
3.32%
1 Month
15.70%
3 Months
-36.36%
6 Months
-23.29%
1 Year
-23.08%
2 Year
-56.86%
Key data
Stock price
$2.80
P/E Ratio 
0.00
DAY RANGE
$2.69 - $2.92
EPS 
-$0.86
52 WEEK RANGE
$1.99 - $8.54
52 WEEK CHANGE
-$25.93
MARKET CAP 
158.648 M
YIELD 
N/A
SHARES OUTSTANDING 
38.052 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-08-2025
BETA 
-0.48
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$178,109
AVERAGE 30 VOLUME 
$173,580
Company detail
CEO: Thomas Zindrick
Region: US
Website: www.genelux.com
Employees: 10
IPO year: 2023
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Genelux is a clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Our principal executive offices are located at 2625 Townsgate Road, Suite 230, Westlake Village, California.

Recent news